Table 2.
Cost-effectiveness for global household contact management interventions for multidrug-resistant and rifampicin-resistant tuberculosis in children younger than 15 years for 2019
| No intervention | HCM only |
HCM and TPT for all children aged <5 years or <15 years living with HIV |
HCM and TPT for all children aged <5 years or <15 years living with HIV or with a positive tuberculin skin test |
HCM and TPT for all children aged <15 years |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Levofloxacin | Moxifloxacin | Delamanid | Bedaquiline | Levofloxacin | Moxifloxacin | Delamanid | Bedaquiline | Levofloxacin | Moxifloxacin | Delamanid | Bedaquiline | |||
| Cost, US$ million | 51 (31 to 80) | 114 (86 to 151) | 117 (90 to 153) | 119 (91 to 154) | 128 (100 to 164) | 119 (92 to 154) | 127 (100 to 162) | 130 (103 to 166) | 157 (128 to 194) | 130 (103 to 164) | 135 (108 to 171) | 140 (113 to 177) | 184 (152 to 223) | 141 (112 to 174) |
| Deaths | 6110 (5230 to 7100) | 3760 (3130 to 4440) | 2890 (2420 to 3410) | 2890 (2420 to 3410) | 2650 (2230 to 3100) | 2650 (2230 to 3100) | 2600 (2180 to 3080) | 2600 (2180 to 3080) | 2280 (1920 to 2660) | 2280 (1920 to 2660) | 2520 (2110 to 2980) | 2520 (2110 to 2980) | 2170 (1830–2530) | 2170 (1830 to 2530) |
| Life-years lost, 3% discounted | 171 000 (145 000 to 199 000) | 105 000 (86 900 to 124 000) | 80 600 (67 300 to 95 200) | 80 600 (67 300 to 95 200) | 73 800 (61 700 to 86 400) | 73 800 (61 700 to 86 400) | 72 600 (60 700 to 86 000) | 72 600 (60 700 to 86 000) | 63 500 (53 500 to 74 300) | 63 500 (53 500 to 74 300) | 70 300 (58 800 to 83 400) | 70 300 (58 800 to 83 400) | 60 400 (50 900–70 700) | 60 400 (50 900 to 70 700) |
| Incremental cost, US$ million | Reference | 63 (40 to 95) | 66 (43 to 97) | 68 (44 to 99) | 77 (53 to 108) | 68 (45 to 99) | 76 (52 to 108) | 79 (55 to 111) | 106 (79 to 141) | 79 (54 to 110) | 84 (59 to 116) | 89 (64 to 122) | 133 (102 to 171) | 90 (63 to 122) |
| Incremental deaths | Reference | −2350 (−2790 to −1940) | −3220 (−3840 to −2690) | −3220 (−3840 to −2690) | −3470 (−4150 to −2880) | −3470 (−4150 to −2880) | −3510 (−4170 to −2930) | −3510 (−4170 to −2930) | −3840 (−4550 to −3220) | −3840 (−4550 to −3220) | −3590 (−4250 to −3010) | −3590 (−4250 to −3010) | −3950 (−4660 to −3330) | −3950 (−4660 to −3330) |
| Incremental life-years saved, 3% discounted | Reference | 65 700 (54 100 to 78 100) | 90 100 (74 600 to 108 000) | 90 100 (74 600 to 108 000) | 96 900 (80 300 to 116 000) | 96 900 (80 300 to 116 000) | 98 000 (81 700 to 117 000) | 98 000 (81 700 to 117 000) | 107 000 (89 600–128 000) | 107 000 (89 600 to 128 000) | 100 000 (83 800 to 119 000) | 100 000 (83 800 to 119 000) | 110 000 (92 600 to 131 000) | 110 000 (92 600 to 131 000) |
| ICER, US$ per DALY | .. | 960 | 738 | 754 | 799 | 703 | 773 | 807 | 992 | 737 | 838 | 890 | 1208 | 814 |
Data are n (95% uncertainty interval) unless otherwise stated. Reference indicates that other cells in the row are calculated as changes relative to this value. US$ are 2020 US$. Global ICERs are for summary comparisons between interventions (figure 3; appendix pp 26–27). DALY=disability-adjusted life-year. ICER=incremental cost-effectiveness ratio. TPT=tuberculosis preventive therapy. HCM=household contact management.